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In 105 pancreatic insufficient CF patients (steatorrhea and low fecal elastase-1 concentrations), the effectiveness of pancreatic enzyme
therapy (PET) has been assessed (fecal fat losses and coefficient of fat reabsorption). Eight unresponsive subjects were checked for PET
compliance with fecal chymotrypsin assay. Three patients were documented to be non-compliant. Unresponsive patients should undergo
evaluation for PET compliance.
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fibrosis (CF). Energy deficiencies result from imbalance
between energy needs, energy supply and its effective use
[1]. Loss of energy via the stool may be one of the factors
leading to a gradual decline in body weight, ultimately
influencing lung function and survival [2], therefore,
exogenous pancreatic enzymes are an important part of CF
therapy. The principles of pancreatic enzyme therapy (PET)
have been described and discussed [1,3]. Optimization of
pancreatic enzyme supplementation should result in medical
(more efficient fat absorption, decrease of therapy-related
risks), psychological (fewer capsules to be swallowed) and
economic benefits (lower therapy costs).
Many CF patients are never tested for maldigestion [4],
and efficacy of PET is not objectively assessed either.
Baker et al. [5] failed to find any correlation between PET
dose and gastrointestinal symptoms, and suggested that
more sensitive outcome measures of the effectiveness of
PET in cystic fibrosis (CF) patients are needed. The lack⁎ Corresponding author. Tel.: +48 61 84800310; fax: +48 61 8483362.
E-mail address: jarwalk@am.poznan.pl (J. Walkowiak).
1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.05.006of objective assessment of PET efficacy in clinical settings
remains a significant problem [2]. Most CF patients are
instructed to take increasing PET doses without checking
efficacy.
In addition to failure to test most CF patients for
pancreatic function or PET efficacy, their compliance to
PET, even in unresponsive and/or malnourished patients may
not be subjected to objective measures either. Therefore, its
real clinical importance remains unclear. The aim of the
present study was to assess objectively patient's compliance
to PET in CF subjects with unresponsive steatorrhea, using a
combination of fecal elastase-1 and fecal chymotrypsin
measurements.
1. Material and methods
The study was started in January 1999 and ended in
December 2002. Subjects were selected out of a cohort of CF
patients attending Department of Gastroenterology and
Metabolism, Institute of Pediatrics, Poznan University of
Medical Sciences and the Department of Pediatrics,
Gastroenterology and Oncology, Institute of Pediatrics,ed by Elsevier B.V. All rights reserved.
Table 1
Basic clinical data of the studied CF patients (selection group, n=8)
Parameter Mean±S.E.M. (range)
Age (years) 12.4±1.6 (5–19)
Fecal elastase-1 (μg/g)a 3.4±1.6 (0–11)
Steatorrhea (g/day)a 24.8±3.2 (16.4–43.1)
CFA (%)a 68.4±2.4 (59.8–78.4)
Energy intake (% RNI) 95.2±4.9 (72.5–116.1)
Fat intake (g/day) 79.3±8.1 (54.1–123.8)
a Normal values: Fecal elastase-1>200 μg/g of feces. Fecal fat excretion:
5–10 years<5 g/day; more than 10 years<7 g/day. CFA>93.0.
Table 2
Fecal tests in non-compliant CF patients
No. Age
(years)
Sex Steatorrhea
(g/day)
CFA
(%)
Fecal chymotrypsin
(U/g)
1 5 F 18.9 65.1 UD 2.3 3.2
2 19 M 43.1 65.2 UD UD UD
3 12 M 32.5 59.8 6.8 1.1 UD
UD – undetectable.
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investigation was approved by the Ethical Committee of the
Poznan University of Medical Sciences, Poland. All patients
and their parents were asked to give an informed consent to
participate the study.
1.1. Patients' selection
Inclusion criteria:
– Patients older than 5 years.
– Pancreatic insufficiency confirmed with fecal elastase-1
test and fecal fat balance study.
– Persistent steatorrhea (>15 g/day) when on high dose of
PET (10000 FIP lipase/kg of body weight/day).
– Willingness to participate the study.
Exclusion criteria:
– Coexistence of any gastrointestinal disease possibly
influencing the assessment of pancreatic status and/or
PET efficacy.
1.2. Subjects
One-hundred and five pancreatic insufficient CF
patients with low fecal elastase-1 (E1) concentrations and
abnormal fecal fat balance (without PET) were pre-selected
for the study. In all pre-selected subjects, fecal fat
excretion on PET was determined. Eight subjects (receiv-
ing maximal dose of PET i.e. 10000 U lipase/kg of body
weigh/day) fulfilled inclusion and exclusion criteria and
were included in the study. Their basic clinical data are
presented in Table 1.
In the 8 selected CF patients nutrient intake for 7 days
was assessed. Fecal fat excretion was determined during
the last 3 days of the nutritional assessment, and the
coefficient of fat absorption (CFA) was calculated [6]. For
the assessment of patients' compliance to PET, fecal
chymotrypsin was measured in three independent samples
during stool collection. In all CF patients with documen-
ted non-compliance, fecal chymotrypsin activity, fecal fat
excretion and fat intake were subsequently assessed once
PET recommendations had been followed.1.3. Methods
Fecal elastase-1 concentration (the test based on
monoclonal antibodies) was measured by an immunoenzy-
matic method (ELISA) [7], and fecal chymotrypsin activity
was measured using a colorimetric method [8]. Fecal fat
was analyzed according to van de Kamer et al. [9]. Daily
fecal fat excretion was defined as a mean of a 72-h collection
period.
The assessment of nutrient intake was based on the
records of 7-day weighed rations. The records of 7-day
weighed rations (with a use of scales accurate to 0.1 g) were
collected at home. Parents and children were given both oral
and written instructions for collecting diet records. The diet
records were reviewed and clarified. The obtained data were
analyzed using a computer database (Microsoft Access 7.0)
prepared based on tables for the composition and nutrition
value of food products [10]. The degree to which the
recommended intake has been met was considered in relation
to values given by the National Institute of Food and
Nutrition in Warsaw [11]. For the examined group, moderate
physical activity was assumed.
1.4. Statistical analysis
If not stated otherwise, values are expressed as mean±
S.E.M.
2. Results
In 3 out of 8 CF patients with persistent steatorrhea, fecal
chymotrypsin activities were lower than 6 U/g. Severe
steatorrhea and low values of CFAwere in concordance with
low fecal chymotrypsin activities (Table 2). In the remaining
five CF patients normal fecal chymotrypsin activities were
found, which ranged from 11.3 to 55.2 U/g for single
measurements and from 18.5 to 46.3 U/g for the mean value
taken from three measurements of independent stool
samples.
One of the patients that was documented to be non-
compliant (No. 2) denied taking enzymes. Since the next
fecal fat balance studies revealed less pronounced steator-
rhea (25.5 and 18.3 g/day) and his nutritional status was
normal (body height and weight above 50th centile) we
accepted his position at that time. However, with progression
of the pulmonary disease he started taking enzymes and he is
Table 3
Changes in fat absorption and body weight in CF patients due to PET
compliance
No Without PET compliance With PET compliance
Steatorrhea
(g/day)
CFA
(%)
Body weight
Z-score
Steatorrhea
(g/day)
CFA
(%)
Body weight
Z-score
1 18.9 65.1 −1.94 5.4 91.3a −1.33
2 43.1 65.2 0.05 8.8 92.1b −0.10
3 32.5 59.8 −1.75 8.9 90.2a −1.35
a 6 months later.
b 2 years later.
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(Table 2).
The remaining two (Nos. 1 and 3) were instructed again
how to follow PET recommendations. The compliance to
PET resulted in significant decrease of fecal fat losses and the
increase of CFA. A significant weight gain within the 3-
month period was observed (Table 3).
3. Discussion
We have documented in the present study that non-
treatable steatorrhea in some CF patients results from the
lack of enzyme supplementation. Introduction of proper PET
in three non-compliant subjects led to the significant
decrease of fecal fat excretion. The increase of energy intake
combined with the improvement of fat absorption resulted in
significant weight gain. The introduction of PPIs was
considered in the remaining 5 subjects once PET compliance
had been documented.
Most CF patients are never tested either for pancreatic
function or for PET efficacy or compliance. Borowitz et al.
[4] proved that some CF patients were misclassified as
pancreatic insufficient and underwent unwarranted therapy.
The authors documented that some patients were also
misclassified as pancreatic sufficient and were not recom-
mended PET. Baker et al. [5] finding no correlation between
PET dose and gastrointestinal symptoms suggested that
more sensitive outcome measures of the effectiveness of PET
in CF patients are needed. In addition, we have proved in the
present study that subjective measures (history) might be not
sufficient for checking PET compliance.
Determination of fecal chymotrypsin has been an
accepted indirect test in pediatric practice for several years
[8,12]. However, it has been shown that fecal elastase-1 is far
more sensitive than fecal chymotrypsin in the assessment of
exocrine pancreatic function in CF [13], and we have
recommended that the fecal chymotrypsin test should be
replaced by the fecal elastase-1 test in the initial determina-
tion of pancreatic status in CF. The fecal elastase-1 test
(ELISA) is specific for the human enzyme and not
influenced by exogenous enzyme supplementation [14],
whereas due to the colorimetric method used, the measure-
ment of chymotrypsin activity is affected2 by enzymesubstitution therapy [15]. Thus, for the assessment of
endogenous pancreatic secretion using fecal chymotrypsin,
PET should be stopped for at least 3 days before the test. On
the other hand, the interference by exogenous enzymes
creates the possibility to check adherence to recommended
pancreatic enzyme supplementation by the measurement of
chymotrypsin activity.
In conclusion, all unresponsive and/or malnourished CF
patients should undergo routine check-up with fecal assay
for PET compliance.
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